Search

Author/Creator Gafanov, Rustem

1. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Issue 10295 (10th July 2021)

Authors:
Sweeney, Christopher; Bracarda, Sergio; Sternberg, Cora N; Chi, Kim N; Olmos, David; Sandhu, Shahneen; Massard, Christophe; Matsubara, Nobuaki; Alekseev, Boris; Parnis, Francis; Atduev, Vagif; Buchschacher, Gary L; Gafanov, Rustem; Corrales, Luis; Borre, Michael; Stroyakovskiy, Daniil; Alves, Gus...
Journal:
Lancet
Issue:
Volume 398:Issue 10295(2021)
Page Start:
131
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Issue 12 (December 2020)

Authors:
Powles, Thomas; Plimack, Elizabeth R; Soulières, Denis; Waddell, Tom; Stus, Viktor; Gafanov, Rustem; Nosov, Dmitry; Pouliot, Frédéric; Melichar, Bohuslav; Vynnychenko, Ihor; Azevedo, Sergio J; Borchiellini, Delphine; McDermott, Raymond S; Bedke, Jens; Tamada, Satoshi; Yin, Lina; Chen, Mei; Molife...
Journal:
Lancet oncology
Issue:
Volume 21:Issue 12(2020)
Page Start:
1563
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search